The invention relates to
nimodipine / ligustrazine double-load
PLGA nanoparticles which are prepared through a method comprising the steps that:
nimodipine, ligustrazine
phosphate and a
polylactic acid-
glycolic acid copolymer are precisely weight according to a
mass ratio of 1:5-20:40-60; the materials are dissolved into
acetone, such that an organic phase is obtained; a PVA water solution with a
mass concentration of 0.5-1.0% is adopted as an aqueous phase; under stirring, the organic phase is slowly dropped into the aqueous phase; when dropping is finished, the mixture is continued to be stirred for 2-4h under a constant temperature of 40-50 DEG C, such that the
organic solvent is volatilized;
centrifugation is carried out; a
sediment is washed 2-3 timed by using
distilled water, and is lyophilized, such that the
nimodipine / ligustrazine double-loading
PLGA nanoparticles are obtained. According to the invention,
PLGA is adopted as a
carrier material, and P-gp inhibitors TMP and NMD are applied in combination, such that NMD / TMP-PLGA-NPs are prepared. Therefore, defects of short
drug half-life, easy generation of
cytotoxicity, and the like of simple combination are avoided, a P-gp
efflux effect is inhibited, and NMD distribution to tissues is promoted. Therefore, the nanoparticles have certain advantages over single-load nanoparticles.